Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $15.27
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$63.68M
Enterprise Value-$36.33
Total Cash (Recent Filing)$136.15M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta0.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,351,456
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.00Price Target Upside-66.10% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable equity base and very low leverage provide durable solvency flexibility, giving the company runway to fund clinical programs and negotiate partnerships without immediate refinancing. This structural cushion reduces short-term solvency risk even as R&D spending continues.
Advanced Clinical Asset (olevaprubart)A Phase 2b-ready, mechanism-differentiated biologic targeting OX40 for atopic dermatitis and alopecia areata represents a durable strategic asset. If clinical outcomes confirm efficacy and safety, this program could establish a sustainable therapeutic franchise and meaningful long-term revenue potential.
Strengthened Financial LeadershipInstalling an experienced biotech finance executive improves capital-allocation credibility and execution of financings or partnerships. Strong finance leadership is a structural positive for managing burn, optimizing R&D spend, and planning longer-term funding strategies.
Bears Say
No Meaningful Operating RevenueThe company is effectively pre-revenue, so it lacks internal cash generation from product sales. This structural absence of operating revenue forces dependence on external capital, making long-term project continuity contingent on successful financings or partnerships.
Sustained Cash BurnConsistent and large negative operating and free cash flows will steadily deplete equity if not offset by financing or revenue. Over a multi‑quarter horizon this creates recurring financing needs that can dilute shareholders and constrain strategic optionality.
Persistent Operating LossesSubstantial recurring operating losses and negative returns on equity indicate R&D and operating spend are not yet value-accretive. If losses persist, they will erode equity and increase pressure for cost control, program prioritization, or asset sales, risking dilution or strategic exits.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $15.27 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $63.68M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Overvalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,351,456 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-66.10% Downside)
$2.00 (-66.10% Downside)
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.47%
Trailing 12-Months
Company Description
ImageneBio
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
IMA Stock 12 Month Forecast
Average Price Target
$2.00
▼(-66.10% Downside)
Technical Analysis
Ownership Overview
32.64% Insiders
3.57% Mutual Funds
9.85% Other Institutional Investors
50.91% Public Companies and
Individual Investors